Suchergebnisse - "Usmani, Saad Z"

PubPharm (54)

1

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk

enthalten in: Blood cancer journal | 2024

von Callander, N. | Silbermann, R. | Kaufman, J. | +33

2

Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data

enthalten in: Advances in therapy | 2024

von Durie, B. | Kumar, S. | Ammann, E. | +5

3

Daratumumab for patients with myeloma with early or late relapse after initial therapy : subgroup analysis of CASTOR and POLLUX

enthalten in: Blood advances | 2024

von Spencer, A. | Moreau, P. | Mateos, M. | +17

4

Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma : TAURUS Chart Review Study

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Gordan, L. | Tan, C. | Vescio, R. | +12

5

Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens

enthalten in: Nature cancer | 2023

von Maura, F. | Boyle, E. | Coffey, D. | +34

6

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN) : final analysis of an open-label, randomised, phase 2 trial

enthalten in: The Lancet. Haematology | 2023

von Voorhees, P. | Sborov, D. | Laubach, J. | +25

CommentIn: Lancet Haematol. 2023 Oct;10(10):e788-e789. - PMID 37793762

7

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study

enthalten in: Blood advances | 2023

von Usmani, S. | Quach, H. | Mateos, M. | +7

8

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma

enthalten in: Blood cancer journal | 2023

von Tan, C. | Derkach, A. | Nemirovsky, D. | +18

UpdateOf: Res Sq. 2023 Feb 24;:. - PMID 36865246

9

A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Bhutani, M. | Foureau, D. | Robinson, M. | +14

10

Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma

enthalten in: Journal of comparative effectiveness research | 2023

von Krishnan, A. | Nooka, A. | Chari, A. | +14

1
2
3
4
5
6
Nächster »
[6]